XML 39 R33.htm IDEA: XBRL DOCUMENT v3.25.3
Organization, Basis of Presentation and Liquidity - Additional Information (Details)
$ in Millions
 1 Months Ended 9 Months Ended
Dec. 17, 2021
USD ($)
Aug. 31, 2025
USD ($)
Jan. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2025
USD ($)
Subject
Segment
ClinicalTrials
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of clinical trials | ClinicalTrials         2
Number of subject in Phase 1 | Subject         5
Number of subject in Phase 1/2a | Subject         25
Clinical development cost         $ 14.3
Additional clinical development cost         $ 7.0
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]         srt:ChiefExecutiveOfficerMember
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description         our CODM uses consolidated net loss to measure segment profit or loss, allocate resources and assess performance
Segment Reporting, Expense Information Used by CODM, Description         CODM reviews and utilizes revenue and functional expenses (cost of royalties, research and development, and general and administrative) at the consolidated level to manage our operations. Other segment items included in consolidated net loss are interest income, loss on marketable equity securities, change in fair value of warrant liability, foreign currency transaction loss, and other income (expense), and the provision for income tax benefit, which are reflected in the condensed consolidated statements of comprehensive income.
Number of operating segments | Segment         1
Number of reportable segments | Segment         1
Cash and cash equivalents and marketable securities         $ 40.5
Parent Company [Member] | ATM Sales Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Amount reserved for future issuance         38.7
Maximum [Member] | Parent Company [Member] | Warrant Liabilities [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Amount reserved for future issuance         $ 35.6
Roche Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront payment $ 50.0   $ 50.0 $ 50.0  
Maximum milestone payments to be received upon performance conditions     $ 620.0 $ 620.0  
Research Collaboration Agreement with William Demant Invest [Member] | Maximum [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Preclinical development research collaboration cost   $ 12.0